Therapeutic Sector Coverage
Sector 01 — Public Arm
Oncology
The largest and most data-rich sector in biopharmaceutical investing. Our Oncology team focuses on mechanistic differentiation — understanding not just whether a drug works, but why, and how its mechanism positions it within an increasingly crowded competitive landscape.
We track modalities from IO combinations and targeted small molecules to cell therapies and antibody-drug conjugates, evaluating each through both biological and clinical lenses.
High Activity Sector
Large-Cap + Small-Cap
Catalyst-Rich
Investment Themes
IO Combination Strategies
ADC Science
CAR-T & Cell Therapy
Targeted Therapies
Tumor Microenvironment
Bispecific Antibodies
RAS/KRAS Targeting
HER2 Biology
BRCA / DDR Pathway
Primary Endpoints Tracked
Overall Survival (OS)
Progression-Free Survival (PFS)
Objective Response Rate (ORR)
Duration of Response (DoR)
Pathological Complete Response (pCR)
Key Analytical Focus Areas
01.
Mechanism of Action Differentiation
What does the drug do that existing treatments don't? How does selectivity, tissue penetration, or target affinity translate to clinical benefit?
02.
Biomarker-Driven Patient Selection
Which patients are most likely to respond? How validated is the companion diagnostic? What does biomarker-negative performance look like?
03.
Combination Strategy & Sequence
In what treatment sequence does the drug perform best? Are combination regimens expanding or cannibalizing addressable markets?
Sector 02 — Public Arm
Central Nervous System
The CNS sector presents some of the most complex and high-risk investment opportunities in biopharma — and therefore some of the most interesting. Failed trials have shaped an entire generation of investor skepticism, creating idiosyncratic opportunities for analysts willing to do the deep scientific work.
Our CNS team focuses on mechanistic biology, surrogate endpoint validity, and the structural challenges of CNS drug delivery — three factors that most investors underweight.
High-Complexity
Long Development Cycles
Endpoint Innovation
Investment Themes
Neurodegeneration (AD, PD, ALS)
Psychiatric Novel MOAs
Antisense Oligonucleotides
BBB Delivery Technologies
Neuroinflammation
Tau vs Amyloid Biology
Biomarker Development
GABA / Glutamate Systems
Primary Endpoints Tracked
CDR-SB (Clinical Dementia Rating)
ADAS-Cog
CSF Biomarkers
Amyloid PET
MADRS / HAM-D
Key Analytical Focus Areas
01.
Surrogate vs Functional Endpoints
Does the trial measure what matters to regulators and payers? How has FDA treated biomarker-based approval in neurodegeneration?
02.
Blood-Brain Barrier Strategy
How does the drug reach the CNS? What delivery technology is employed and what are the toxicity and manufacturability implications?
03.
Patient Selection & Disease Staging
Early vs late disease staging has derailed many CNS programs. Is the trial population right for the mechanism being tested?
Sector 03 — Public Arm
Rare Disease
Rare disease investing rewards analysts who can master small patient populations, unconventional regulatory pathways, and pricing dynamics that operate outside normal market logic. Natural history data, surrogate endpoints, and basket trial design all require specialized knowledge.
Our Rare Disease team analyzes the intersection of genetic causality, enzyme biology, and the regulatory frameworks — Orphan Drug, Breakthrough Designation, Accelerated Approval — that define development timelines in this sector.
Orphan Drug Designation
Small Patient Populations
High-Pricing Dynamics
Investment Themes
Lysosomal Storage Disorders
Enzyme Replacement Therapy
Substrate Reduction
Orphan Drug Economics
Breakthrough Designation
Natural History Studies
Basket Trial Design
Registry Data
Primary Endpoints Tracked
6-Minute Walk Test
Enzyme Activity Levels
Biomarker Normalization
Natural History vs Treated
Event-Free Survival
Key Analytical Focus Areas
01.
Genetic Causality & Penetrance
Is the disease fully penetrant? Is there genotype-phenotype correlation? These factors determine how cleanly a drug can be developed and priced.
02.
Regulatory Pathway Selection
Accelerated Approval, Breakthrough Therapy, and PRIME designations all imply different probability-of-approval curves and approval timelines.
03.
Pricing & Market Access
In rare disease, pricing power is extraordinary — but increasingly subject to HTA scrutiny in ex-US markets. How sustainable is the pricing model?
Sector 04 — Public Arm
Genetic Medicine
Gene therapy and genetic medicine represent one of the most technically demanding and rapidly evolving areas of drug development. Our Genetic Medicine team goes deep on vector biology, editing precision, delivery mechanisms, and durability — the factors that most determine long-term clinical and commercial success.
From AAV tropism to in vivo CRISPR delivery to lipid nanoparticle chemistry, we track the organization science that underlies each asset's differentiation potential.
Organization-Driven
Long Durability Horizon
Mfg. Cost Risk
Investment Themes
AAV Gene Therapy
CRISPR / Base Editing
mRNA Therapeutics
Lipid Nanoparticles
Ex Vivo Gene Editing
Durability of Effect
Manufacturing Scale
Redosing Strategies
Primary Endpoints Tracked
Factor Level Expression
Annualized Bleed Rate
HbF Levels (Hemoglobin)
Vector Genome Copies
Liver Enzyme Markers
Key Analytical Focus Areas
01.
Vector Tropism & Immunogenicity
Does the AAV serotype or delivery vehicle reach the target tissue efficiently? What are the pre-existing immunity rates in the target population?
02.
Durability of Therapeutic Effect
How long does the effect last? Is the durability data mature? One-time cure pricing depends entirely on durability credibility.
03.
Manufacturing & COGS Trajectory
Gene therapy manufacturing is among the most complex in biopharma. What is the cost trajectory at commercial scale, and how does it affect long-term margin?
Sector 05 — Public Arm
Immunology & Inflammation
Immunology and inflammation sit at the intersection of autoimmune disease, oncology immunotherapy, and transplant medicine — creating one of the broadest and most commercially mature areas of biopharma. Our I&I team tracks cytokine biology, T-cell pathobiology, and the increasingly crowded IL-pathway inhibitor landscape.
With blockbuster franchises now facing biosimilar pressure and next-generation IL inhibitors entering crowded markets, differentiation analysis is more critical than ever in this sector.
Blockbuster Territory
Biosimilar Dynamics
Broad Indication Potential
Investment Themes
IL-4/13 Pathway
JAK Inhibitor Safety
B-Cell Biology
T-Cell Exhaustion
Complement Cascade
Bispecific Antibodies
Oral Small Molecule I&I
Next-Gen IL Inhibitors
Primary Endpoints Tracked
PASI 75/90/100
ACR20/50/70
eGFR (Renal endpoints)
Flare Rate
Steroid-Free Remission
Key Analytical Focus Areas
01.
Cytokine Pathway Biology
Which cytokines are driving disease in the target indication? How upstream vs downstream is the target? What is the risk of immune suppression?
02.
Indication Expansion Optionality
I&I drugs often carry valuable indication expansion optionality. Modeling the full indication landscape can reveal significant hidden value or overestimation risk.
03.
Biosimilar Competitive Dynamics
How does biosimilar entry affect pricing, market share, and the commercial profile of follow-on drugs competing with legacy branded products?